This article is the fourth part of an 8-part series from the authors. The series, Waiting for new drugs for rare ...
By Nigel Rawson and John Adams, November 23, 2022 For seven years, the Patented Medicines Prices Review Board (PMPRB) – ...
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, November 2, 2022 This month marks ...
This article originally appeared in the Financial Post. By Richard C. Owens, July 20, 2022 In the celebrated TV drama, The ...
By Richard C. Owens with Rebecca Rosenberg and Haya Sardar June 28, 2022 PDF of paper Executive Summary Canada’s Patented ...
By determinedly reducing revenues Canada not only ensures the unavailability of existing medications, it sees to it that far fewer ...
Negotiations to limit drug prices should not limit patients’ access to innovative drugs, writes Nigel Rawson. By Nigel Rawson, February ...
Adopting single-payer coverage is not the solution to the challenges facing Canada’s pharmacare system, writes Sean Speer. By Sean Speer, ...
The federal government is proposing dramatic changes to the pricing of new patented medicines in Canada, and it announced in ...
MEDIA RELEASE OTTAWA June 13, 2013 - International trade negotiations with the European Union and the Trans-Pacific Partnership are creating ...
In the March 2012 issue of Policy Options released by the Institute for Research on Public Policy, MLI Managing Director Brian Lee Crowley ...
May 3, 2012 - In today's Windsor Star, MLI author Kristina Lybecker recommends changes to Canadian legislation that would help strengthen ...
